Delivery Order SPE2DB22D1106-SPE2DB25FEVH1
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,712.23 to AmerisourceBergen Drug Corp on September 19, 2025, for Lupron Depot 11.25 mg 3-month kits, with an ultimate completion date of September 22, 2025. The contract employs firm fixed-price pricing with no set-aside designation, indicating competitive award to the vendor. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate...
- The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order valued at $49,219.01 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,568,249,853 units of Lupron Depot 3.75 mg kits. This award does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999,999,999.00, which provides a comprehensive global...
- The Defense Logistics Agency (DLA) awarded a $17,899.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Lupron Depot 3.75 mg kits, with an ultimate completion date of July 22, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 6, 2025, for the supply of Lupron Depot 11.25 mg 3-month treatment kits, with a contract ceiling value of $4,585.94 and an ultimate completion date of June 9, 2025. This is a firm fixed-price delivery order placed under a competitive procurement with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania—which is also the place of...
- The Defense Logistics Agency awarded a delivery order valued at $7,404.32 to AmerisourceBergen Drug Corp for the supply of Lupron Depot 11.25 mg 3-month kits. The contract is structured as a firm fixed price delivery order with an ultimate completion date of June 3, 2025, and represents a non-set-aside competitive award. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a $10,511.82 firm fixed price delivery order to AmerisourceBergen Drug Corp for Lupron Depot 11.25 mg 3-month kits, with an ultimate completion date of July 18, 2025. This non-set-aside competitive award represents a single delivery order issued under AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,201.87 for Lupron Depot 11.25 mg 3-month kits, with an ultimate completion date of September 4, 2025. This is a firm fixed price delivery order under a non-set-aside competitive procurement. The contractor, headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $52,189.74 to AmerisourceBergen Drug Corp for Lupron Depot 11.25 mg 3-month kits. This is a firm fixed-price, competitively awarded contract with a completion date of September 29, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered from the company's location in Conshohocken, Pennsylvania, where the company...
- The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order valued at $4,926.04 to Amerisourcebergen Drug Corp, the Corporate Office Division of Amerisourcebergen Corporation, a major pharmaceutical distributor. The contract is for the supply of LUPRON DEPOT 11.25 MG 3MO KITS, with a performance period ending on May 10, 2024. This award is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order valued at $52,671.42 to AmerisourceBergen Drug Corp for the supply of Lupron Depot 11.25 mg 3-month kits under a firm fixed price contract type. The award, made on September 17, 2025, with an ultimate completion date of September 18, 2025, represents a non-competitive delivery order issued against the company's existing Indefinite Delivery Contract (IDC). AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FEVH1Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $27,562.95 to AmerisourceBergen Drug Corp for Lupron Depot 11.25 mg 3-month kits, with a firm fixed price and ultimate completion date of June 27, 2025. This non-set-aside, competitively awarded contract represents a pediatric pharmaceutical delivery under the company's existing DLA contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through its extensive portfolio of brand-name and generic medications, vaccines, and medical supplies. This delivery order is issued under AmerisourceBergen Drug Corp's prime Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The parent contract serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, with customers including the Defense Health Agency and U.S. Coast Guard. The contract framework demonstrates the company's capability to fulfill federal medical supply requirements through open competition and reflects its position as a key pharmaceutical provider within the DLA Medical Supply Chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.6k | 6/26/25 |